--- title: "RemeGen Co., Ltd. (688331.SH)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/688331.SH.md" symbol: "688331.SH" name: "RemeGen Co., Ltd." industry: "Biotechnology" datetime: "2026-05-20T02:03:49.241Z" locales: - [en](https://longbridge.com/en/quote/688331.SH.md) - [zh-CN](https://longbridge.com/zh-CN/quote/688331.SH.md) - [zh-HK](https://longbridge.com/zh-HK/quote/688331.SH.md) --- # RemeGen Co., Ltd. (688331.SH) ## Company Overview RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | CN Market | | Website | [www.remegen.cn](https://www.remegen.cn) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: B > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-19T04:30:08.000Z **Overall: B (0.28)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 4 / 81 | | Industry Median | C | | Industry Average | C | - **Style**: Growth - Stocks whose main business is in the growth stage. - **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock. **Multi Score**: B #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 76.81% | | | Net Profit YoY | 194.05% | | | P/B Ratio | 16.09 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 63149828290.49 | | | Revenue | 3378068039.31 | | #### Multi Score Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 45.33% | A | | Profit Margin | 38.20% | A | | Gross Margin | 82.18% | A | | Revenue YoY | 76.81% | A | | Net Profit YoY | 194.05% | A | | Total Assets YoY | 38.77% | A | | Net Assets YoY | 121.77% | A | | Cash Flow Margin | 19.55% | D | | OCF YoY | 76.81% | A | | Turnover | 0.53 | C | | Gearing Ratio | 46.66% | C | ```chart-data:radar { "title": "Longbridge Financial Score - RemeGen Co., Ltd.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "76.81%", "rating": "" }, { "name": "Net Profit YoY", "value": "194.05%", "rating": "" }, { "name": "P/B Ratio", "value": "16.09", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "63149828290.49", "rating": "" }, { "name": "Revenue", "value": "3378068039.31", "rating": "" } ] }, { "name": "Multi Score", "grade": "B", "indicators": [ { "name": "ROE", "value": "45.33%", "rating": "A" }, { "name": "Profit Margin", "value": "38.20%", "rating": "A" }, { "name": "Gross Margin", "value": "82.18%", "rating": "A" }, { "name": "Revenue YoY", "value": "76.81%", "rating": "A" }, { "name": "Net Profit YoY", "value": "194.05%", "rating": "A" }, { "name": "Total Assets YoY", "value": "38.77%", "rating": "A" }, { "name": "Net Assets YoY", "value": "121.77%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "19.55%", "rating": "D" }, { "name": "OCF YoY", "value": "76.81%", "rating": "A" }, { "name": "Turnover", "value": "0.53", "rating": "C" }, { "name": "Gearing Ratio", "value": "46.66%", "rating": "C" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 49.15 | 21/81 | 116.36 | 105.82 | 54.46 | | PB | 16.16 | 74/81 | 24.57 | 22.01 | 19.79 | | PS (TTM) | 18.78 | 67/81 | 26.15 | 23.20 | 19.73 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A | | 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A | | 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B | | 04 | RemeGen (688331.SH) | A | A | C | C | B | B | | 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-05-14T16:00:00.000Z Total Analysts: **6** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 3 | 50% | | Overweight | 1 | 17% | | Hold | 2 | 33% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 115.60 | | Highest Target | 158.75 | | Lowest Target | 96.63 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688331.SH/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688331.SH/norm.md) - [Related News](https://longbridge.com/en/quote/688331.SH/news.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**